Friday, October 30, 2026

Nautilus Stock Soars 30% In 10 Sessions: Is The Upswing Here To Stay?

ViaNews Editorial Team

December 11, 2023

Nautilus Stock Soars 30% In 10 Sessions: Is The Upswing Here To Stay?

(VIANEWS) - Nautilus (NLS) shares have seen their stock price increase by 30.16% in just 10 sessions, beginning from EUR0.63 on November 27th to EUR0.82 at 18:01 EST on Monday evening - a remarkable surge which followed three consecutive sessions of gains on the NYSE index and culminating with Nautilus closing at a 71.67% discount to its 52-week high of EUR2.17 on November 27th. Investors and analysts have taken notice, many offering speculation as to what may be driving such growth.

About Nautilus

Nautilus, Inc. is a fitness solutions company that designs, sources and markets cardio and strength fitness products to consumers through two segments - Direct and Retail - offering various Nautilus, Bowflex, Schwinn products as well as digital fitness platform JRNY under various brand names (Naulius, Bowflex, Schwinn). As well as selling directly through various channels to consumers through various brands it also licenses intellectual properties related to these brands & intellectual properties patented. Established in 1986 and headquartered in Vancouver Washington with customers serving customers throughout North America Canada Europe the Middle East Africa as well as International customers worldwide.

Yearly Analysis

As per the available data, Nautilus stock has fallen substantially in value since reaching a 52-week high of EUR2.17 last September while remaining above its 52-week low of EUR0.64. This indicates a sharp drop in its valuation over time. Nautilus anticipates experiencing negative 2.8% sales growth this year, which may cause cause concern. However, they anticipate experiencing positive 9% sales growth next year which could indicate potential recovery efforts by Nautilus. Nautilus currently stands with an EBITDA score of 0.19, which indicates its earnings before interest, taxes, depreciation and amortization are relatively low - possibly an indicator of financial weakness for Nautilus. Overall, investors should remember that stock markets can be unpredictable and investing in any stock entails risks. Based on available data, Nautilus appears to be trading below its 52-week high and anticipated negative sales growth this year but possible positive growth next year; additionally EBITDA levels appear low at present. As always before making any investment decisions it is advised that further research be completed or consulting a financial advisor is conducted first.

Technical Analysis

Nautilus' stock value has recently seen an uptick, surpassing both its 50-day moving average of EUR0.75, but falling significantly short of its 200-day average of EUR1.14. This may indicate that its short-term price gain has exceeded that of its long-term average; furthermore, trading activity appears to be above its normal volume of 203301; further supporting this notion. Nautilus' intraday variation average has been consistently positive over the past week, month, and quarter, suggesting a relatively stable trend. Nonetheless, its highest average weekly volatility amplitude was 8.38% which may signal some short-term uncertainty or volatility. Stochastic oscillator measurements show that Nautilus stock is currently oversold (=20), suggesting it may be undervalued and due for an impending rebound. As with all investments, investors should exercise caution and conduct further research prior to making their final investment decisions.

Quarter Analysis

According to available data, Nautilus currently experiences negative sales growth of 20.2%; however, its anticipated quarterly and yearly growth rates are estimated at 36.6% and 82.9%, respectively. Nautilus has achieved year-on-year quarterly revenue growth of 61.7% in its twelve trailing months - totaling an impressive 735.32M in total revenue growth over this time. Overall, investors should take notice of Nautilus' negative sales growth for this quarter as well as its positive projections for coming quarters and revenue growth over the last year as indicators for its financial performance. But it should also be kept in mind that investing in stocks always involves risks; investors should conduct their own analysis before making any definitive investment decisions.

Equity Analysis

Nautilus Inc. currently boasts a relatively high dividend yield of 4.09%; however, their trailing twelve month earnings per share (EPS) were negative at EUR-1.63 suggesting they may not yet be profitable. Their return on equity of 75.4% suggests they may have significant profit relative to shareholder's equity. investors should keep in mind that negative EPS figures might not be cause for alarm if a company is investing heavily in growth and has an optimistic view for future earnings. But investors must still carefully evaluate other factors, including competitive position, industry trends and overall economic conditions when making any investment decisions. Given the limited data provided herein, conducting additional research is recommended in order to make sound decisions regarding investments.

More news about Nautilus (NLS).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,503 source documents archived
Query this data → isubstrate.com